The global Metabolic Disorder Therapeutics market is projected to reach US$ 64560 million in 2029, increasing from US$ 46680 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Metabolic Disorder Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Segment by Type
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
Segment by Application
Oral
Parenteral
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Metabolic Disorder Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Lysosomal Storage Diseases
1.2.3 Diabetes
1.2.4 Obesity
1.2.5 Inherited Metabolic Disorders
1.2.6 Hypercholesterolemia
1.3 Market by Application
1.3.1 Global Metabolic Disorder Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oral
1.3.3 Parenteral
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disorder Therapeutics Market Perspective (2018-2029)
2.2 Metabolic Disorder Therapeutics Growth Trends by Region
2.2.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Metabolic Disorder Therapeutics Market Dynamics
2.3.1 Metabolic Disorder Therapeutics Industry Trends
2.3.2 Metabolic Disorder Therapeutics Market Drivers
2.3.3 Metabolic Disorder Therapeutics Market Challenges
2.3.4 Metabolic Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2022
3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorder Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2024-2029)
5 Metabolic Disorder Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size (2018-2029)
6.2 North America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Metabolic Disorder Therapeutics Market Size by Country (2018-2023)
6.4 North America Metabolic Disorder Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size (2018-2029)
7.2 Europe Metabolic Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2018-2023)
7.4 Europe Metabolic Disorder Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metabolic Disorder Therapeutics Market Size (2018-2029)
9.2 Latin America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Metabolic Disorder Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Detail
11.1.2 Novo Nordisk A/S Business Overview
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.1.5 Novo Nordisk A/S Recent Development
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Detail
11.2.2 Sanofi S.A. Business Overview
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.2.5 Sanofi S.A. Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Detail
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Detail
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.4.5 Eli Lilly and Company Recent Development
11.5 Merck KgaA
11.5.1 Merck KgaA Company Detail
11.5.2 Merck KgaA Business Overview
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.5.5 Merck KgaA Recent Development
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Detail
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.6.5 Amgen, Inc. Recent Development
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Detail
11.7.2 AstraZeneca PLC Business Overview
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.7.5 AstraZeneca PLC Recent Development
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Actelion Pharmaceuticals Ltd. Company Detail
11.8.2 Actelion Pharmaceuticals Ltd. Business Overview
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.8.5 Actelion Pharmaceuticals Ltd. Recent Development
11.9 Shire PLC
11.9.1 Shire PLC Company Detail
11.9.2 Shire PLC Business Overview
11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.9.5 Shire PLC Recent Development
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Detail
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.10.5 AbbVie, Inc. Recent Development
11.11 Biocon Ltd.
11.11.1 Biocon Ltd. Company Detail
11.11.2 Biocon Ltd. Business Overview
11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.11.5 Biocon Ltd. Recent Development
11.12 BioMarin Pharmaceutical, Inc.
11.12.1 BioMarin Pharmaceutical, Inc. Company Detail
11.12.2 BioMarin Pharmaceutical, Inc. Business Overview
11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.12.5 BioMarin Pharmaceutical, Inc. Recent Development
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Detail
11.13.2 Bristol-Myers Squibb Company Business Overview
11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.13.5 Bristol-Myers Squibb Company Recent Development
11.14 Cipla, Inc.
11.14.1 Cipla, Inc. Company Detail
11.14.2 Cipla, Inc. Business Overview
11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.14.5 Cipla, Inc. Recent Development
11.15 CymaBay Therapeutics, Inc.
11.15.1 CymaBay Therapeutics, Inc. Company Detail
11.15.2 CymaBay Therapeutics, Inc. Business Overview
11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2018-2023)
11.15.5 CymaBay Therapeutics, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
*If Applicable.